| Drug General Information |
| Drug ID |
D09CKT
|
| Former ID |
DNC002353
|
| Drug Name |
LY433222
|
| Indication |
Depression [ICD9: 311; ICD10:F30-F39]
|
Investigative |
[1]
|
|---|
| Therapeutic Class |
Psychiatric
|
| Company |
Lilly
|
| Target and Pathway |
| Target(s) |
5-hydroxytryptamine 2A receptor |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
PANTHER Pathway
|
5HT2 type receptor mediated signaling pathway
|
|
Reactome
|
Serotonin receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
GPCRs, Other
|
| References |
| REF 1 | Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23. |
|---|
